The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | Video pages | Webcast | Epidemiological and clinicopathological characteristics of vascular-limited renal AL amyloidosis

Epidemiological and clinicopathological characteristics of vascular-limited renal AL amyloidosis

ERA Journal Club

Access the article here

Speaker
Camille Cohen, France

Panellist
Jack Wetzels, The Netherlands

Moderators
Amaryllis Van Craenenbroeck, Belgium
Andreas Kronbichler, Austria